Allergy Immunotherapy Market Size, Share & COVID-19 Analysis, By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy), Application (Allergic Rhinitis, Allergic Asthma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Online Pharmacies), Regional Forecast, Industry Players, Growth Statistics Report 2023-2030

Market Outlook:

Allergy Immunotherapy Market size surpassed USD 1.5 Billion in 2022 and is poised to reach USD 3.52 Billion, growing at over 10.92% CAGR between 2023 and 2030. The market is driven by factors such as rising prevalence of allergic conditions, increasing demand for long-term treatment options, and advancements in research and development activities. Allergy immunotherapy, also known as allergy shots or vaccines, is a specialized treatment that helps the body build immunity against specific allergens. This therapy involves exposing patients to small doses of allergens over time to reduce their sensitivity and alleviate symptoms.

• Base Year Value (2022): USD 1.5 Billion
• CAGR (2023-2030): 10.92%
• Forecast Year Value (2030): USD 3.52 Billion
• Historical Data Period: 2018-2021
• Largest Region: North America
• Forecast Period: 2023-2030

Market Dynamics:

Growth Drivers & Opportunities:

1. Increasing Prevalence of Allergic Conditions: The global population affected by allergies is on the rise, which is one of the key factors driving the demand for allergy immunotherapy. Allergic conditions such as asthma, hay fever, food allergies, and allergic rhinitis have become increasingly common across different age groups and geographies.

2. Long-term Treatment Option: Allergy immunotherapy offers a long-term solution to manage and prevent allergies. Unlike symptomatic treatments, such as antihistamines, immunotherapy aims to modify the immune system's response, providing patients with long-lasting relief. This factor has contributed to the growing adoption of allergy immunotherapy.

3. Advancements in Research and Development: Continuous advancements in research and development activities have led to the discovery of new treatment techniques and improved immunotherapeutic options. Collaborations between academic institutions, pharmaceutical companies, and research organizations have resulted in the development of more effective and targeted therapies.

 

Industry Restraints & Challenges:

Report Scope

Report Coverage	Details
Segments Covered	By Type; By Application; By Distribution Channel
Regions Covered	• North America (United States, Canada, Mexico)   • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe)   Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC)   • Latin America (Argentina, Brazil, Rest of South America)   • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	ALK, Stallergenes Greer, Allergy Therapeutics, HAL Allergy B.V., HollisterStier Allergy, Zhejiang Wolwo Bio-pharmaceutical Co., LETIPharma, Dermapharm Holding SE

1. High Cost of Treatment: Allergy immunotherapy can be expensive, especially when considering the long-term treatment duration. The need for multiple injections and regular monitoring add to the overall cost, making it relatively inaccessible for some patients. The high cost acts as a potential restraint to the market's growth.

2. Limited Awareness and Accessibility: Lack of awareness about allergy immunotherapy and its benefits remains an obstacle in several regions. Additionally, limited accessibility to specialized healthcare facilities offering immunotherapy treatments is a challenge, particularly in low-income countries and rural areas.

3. Risk of Adverse Reactions: Although allergy immunotherapy is generally safe, there is a risk of adverse reactions, particularly during the initial stages. This can include injection site reactions, allergic reactions, or even anaphylaxis in rare cases. The associated risks and safety concerns may hinder the widespread adoption of immunotherapy.

In conclusion, the allergy immunotherapy market is expected to witness significant growth due to increasing allergic conditions, the demand for long-term treatment options, and advancements in research and development. However, challenges such as the high cost of treatment, limited awareness, and potential adverse reactions must be addressed to fully capitalize on the market's potential.

Regional Forecast:

The allergy immunotherapy market is expected to experience significant growth in various regions across the globe, including North America, Asia Pacific, and Europe.

North America:

The North American region is expected to dominate the allergy immunotherapy market in terms of revenue during the forecast period. This can be attributed to the high prevalence of allergies, increasing research activities, and the availability of advanced healthcare infrastructure in this region. Additionally, the rising awareness among people regarding the benefits of allergy immunotherapy and the presence of key market players further contribute to the growth of this market in North America.

Asia Pacific:

The Asia Pacific region is expected to witness substantial growth in the allergy immunotherapy market. Factors such as the increasing prevalence of allergies, rising healthcare expenditure, and the growing adoption of advanced treatment options drive the market growth in this region. Moreover, the presence of a large target patient population and favorable government initiatives to improve healthcare facilities significantly contribute to the expansion of the allergy immunotherapy market in Asia Pacific.

Europe:

Europe is anticipated to register significant growth in the allergy immunotherapy market. The region showcases a high prevalence of allergic disorders, which drives the demand for allergy immunotherapy. Additionally, the presence of major pharmaceutical companies, ongoing research activities, and favorable reimbursement policies in European countries further propel the market growth in this region.

Segmentation Analysis:

The allergy immunotherapy market can be segmented based on treatment type, allergen type, and end-user.

1. Sub-Segment: Subcutaneous Immunotherapy (SCIT)

Subcutaneous immunotherapy (SCIT), also known as allergy shots, involves the administration of allergen extracts through injections under the skin to desensitize the patient's immune response. SCIT is considered one of the most effective forms of allergy immunotherapy for treating severe allergic diseases, such as asthma and allergic rhinitis. The desensitization process involves gradually increasing doses of specific allergens over a period of time to build tolerance. SCIT has shown long-lasting effects and is suitable for patients who do not respond well to medication or wish to decrease their reliance on drugs.

Competitive Landscape:

The allergy immunotherapy market comprises several key players who are actively involved in research, development, and commercialization of innovative allergy immunotherapy products. These players utilize strategies such as collaborations, partnerships, mergers and acquisitions, and product launches to strengthen their market position. Some of the prominent players in the market include:

1. Aimmune Therapeutics Inc.

2. ALK-Abelló A/S

3. Allergy Therapeutics

4. DBV Technologies

5. HAL Allergy Group

6. Merck & Co., Inc.

7. Stallergenes Greer plc

8. Allergopharma (Merck KGaA)

9. Biomay AG

10. Circassia

These market players focus on offering a diverse range of allergy immunotherapy products and constantly strive to enhance their product portfolio through extensive research and development activities.